摘要
目的:观察传统中药肉桂挥发油中桂皮醛的细胞毒作用,并以小鼠S180移植性肿瘤为模型,进行其体内外抗肿瘤活性及对S180荷瘤小鼠免疫功能影响的实验。方法:实验于2005-03/06在解放军第四军医大学药学系药物研究所实验室完成。取BALB/c小鼠60只,雌雄各半,体质量18～22g。先设1组不接种瘤株的生理盐水正常对照组,10只,雌雄各半。余50只小鼠每只右腋皮下接种0.2mL,24h后随机分成5组,即生理盐水荷瘤对照组,卡铂阳性药对照组,桂皮醛25,50,100mg/kg3个剂量组,每组10只,雌雄各半。用四甲基偶氮唑蓝法观察桂皮醛对6种人癌细胞的体外抗肿瘤作用;对25,50,100mg/kg3个剂量组分别腹腔注射相应剂量用含0.5%土温80生理盐水溶解的桂皮醛(购自中国医药集团上海化学试剂公司),正常对照组和荷瘤空白对照组腹腔注射生理盐水,阳性药对照组腹腔注射卡铂5mg/kg。接种第2天开始全部腹腔注射给药,10mL/kg,每天1次,连续给药10d,于最后1次给药后次日处死动物,测定肿瘤抑制率、免疫器官质量、血常规、NK细胞活性、T淋巴细胞转化率,分析其对小鼠体内抗肿瘤作用及与免疫调节的关系。结果:参加实验的动物60只全部进入结果分析,没有脱失。①桂皮醛对体外培养的6种人肿瘤细胞有直接细胞毒作用,其IC50的范围为12.3～37.1mg/L。②桂皮醛50,100mg/kg剂量组对S180荷瘤小鼠肿瘤生长有明显抑制作用,抑瘤率分别为33.08%和46.92%;同时能有效保护荷瘤小鼠胸腺和脾脏指数。③桂皮醛25,50mg/kg剂量组可以升高白细胞,与生理盐水荷瘤对照组比差异有显著性意义(11.13±1.49,11.25±2.18,8.78±1.33,P<0.01)。④桂皮醛25,50mg/kg剂量组的T淋巴细胞增殖能力显著或非常显著高于生理盐水荷瘤对照组(P<0.05～0.01);桂皮醛50mg/kg剂量组NK细胞杀伤活性明显高于生理盐水荷瘤对照组(P<0.05)。⑤桂皮醛100mg/kg剂量组显著降低白细胞(P<0.01);抑制T淋巴细胞增殖能力和NK细胞杀伤活性,与荷瘤空白对照组比较差异有显著性意义(P<0.01)。结论:桂皮醛对体外培养的肿瘤细胞增殖具有良好的抑制作用,在适当剂量范围内可以保护和恢复荷瘤小鼠的免疫功能。
AIM： To observe cytotoxicity of cinnamaldehyde （CA） on activity of tumor and immunological function of S180 sarcoma in mice in vitro and in vivo on the basis of S180 transplanted-tumor model. METHODS： The experiment was completed in the Laboratory of Medical Institute, School of Pharmacy, Fourth Military Medical University of Chinese PLA from March to June 2005. Totally 60 BALB/c mice of half gender weighting 18-22 g were selected in this study. Ten mice of half gender were not inoculated with tumor saline were regarded as normal control group. Other 50 mice were inoculated subcutaneously with 0.2 mL saline in right axilla. After 24 hours, mice of half gender were randomly divided into 5 groups： saline tumor control group, carboplatin positive control group, 25, 50 and 100 mg/kg CA groups with 10 in each group. Effect of CA on anti-tumor in vitro of 6 human cancer ceils was observed by measurement of trititaed thymidine incorporation. Mice in 25, 50 and 100 mg/kg CA groups were injected intravenously with the relevant dosages of CA dissolved with saline containing 0.5% Tween-80 （provided by Shanghai Chemical Reagent Company of Chinese Medical Group）; mice in normal control group and tumor blank control group were injected intravenously with saline, and mice in positive-drug control group were injected intravenously with 5 mg/kg carboplatin. From the second day of inoculation, all mice were injected intravenously with the dosage of 10 mL/kg, once a day for 10 days. The next day of the last administration, mice were sacrificed to assay inhibitory rate of tumor, mass of immune organs, blood routine, activity of NK cell and transformation efficiency of T lymphocyte, and to analyze the relationship between anti-tumor effect and immunoloregulation of mice in vivo. RESULTS： All 60 mice entered the final analysis without any loss. ① CA had direct toxicity on six human tumor cells cultured in vitro by IC50 values in the range of 12.3 to 37.1 mg/L. ② 50 and 100 mg/kg CA could inhibit the growth of S180 tumor in mice and inhibitory rate were 33.08% and 46.92% respectively, Meanwhile, it could also protect indexes of thymus and spleen of tumor mice.③ Numbers of leucocyte were increased in 25 and 50 mg/kg CA groups, and there was significant difference from those in saline tumor control group （11,13±1.49. 11,25±2,18, 8,78±1,33, P 〈 0,01）, ④Proliferated ability of T lymphocyte in 25 and 50 mg/kg CA groups was remarkably or significantly remarkably higher than that in saline tumor control group （P 〈 0,05-0,01）, Killing activity of NK cell in 50 mg/kg CA group was higher than that in saline tumor control group （P 〈 0.05）. ⑤Numbers of leucocyte were decreased in 100 mg/kg CA group, and there was significant difference of inhibitory ability of proliferation of T lymphocyte and killing activity of NK cell from those in tumor blank control group （P 〈 0.05）.
CONCLUSION： CA has an effect on inhibiting proliferation of malignant tumor cultured in vitro and it can protect and restore the immunological function at appropriate dosage.
出处
《中国临床康复》
CSCD
北大核心
2006年第11期107-110,共4页
Chinese Journal of Clinical Rehabilitation
